Google DeepMind has launched a programme to turn AI on biological threats. The London lab and its sister company Isomorphic Labs call it bioresilience, and set it out in a joint blog post.
The aim is twofold. DeepMind wants to stop people misusing its models, and to help governments, scientists and biosecurity groups use AI to prevent, detect and respond to outbreaks. It says it has built more than 15 such partnerships over the past year.
What the programme covers
On prevention, DeepMind runs a four-step safety process: threat modelling, evaluations, mitigations and monitoring. It is also adapting its SynthID watermarking to biology, so DNA-synthesis providers could screen for risky AI-generated sequences.
For detection, the company is using its AlphaEvolve agent to speed up the algorithms behind pathogen sequencing. That, it says, makes tracking new outbreaks faster and cheaper.
On response, DeepMind is giving trusted researchers access to its latest models to help design vaccines and other countermeasures. Isomorphic Labs has set up a unit to deploy its drug design engine during outbreaks.
Access, with limits
DeepMind is widening access to some models and agents for trusted governments, researchers and biosecurity partners. It classes these as “low-risk” restricted releases, not public launches, Axios reported.
The company says it has controls to match. “If … we were to find that we were reaching a critical capability level and we didn’t have the appropriate mitigations, then we would not be launching,” Helen King, DeepMind’s vice president of responsibility, told Axios. She said that threshold had not been reached.
Part of a wider safety push
The programme lands days after DeepMind chief Demis Hassabis called for governments to set up a standards body for frontier AI. Rival labs are debating similar guardrails, from testing rules to a proposed pause on frontier AI. It sits within DeepMind’s work on chemical, biological, radiological and nuclear risk.
Google has spent years at the meeting point of AI and biology. AlphaFold, its protein-structure tool, won Hassabis and John Jumper a share of the 2024 Nobel Prize in Chemistry. Isomorphic Labs now commercialises that work for drug discovery.
Get the TNW newsletter
Get the most important tech news in your inbox each week.